ReviewInternal medicine (Tokyo, Japan)2026
Olanzapine and the Spectrum of Drug-induced Diabetes: Unveiling Dual Risk Factors for Type 2 Diabetes and Acute-onset Ketoacidosis.
Review in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olanzapine, a widely prescribed atypical antipsychotic, is associated with significant metabolic side effects including hyperglycemia and new-onset diabetes mellitus. While it often contributes to or mimic conventional type 2 diabetes through weight gain and insulin resistance, olanzapine can also induce a distinct, acute, ketosis-prone form of diabetes characterized by acute, severe hyperglycemia, and a high risk of diabetic ketoacidosis (DKA). This review summarizes the current understanding of olanzapine's multifaceted diabetogenic mechanisms, distinguishing its contributions to both type 2 diabetes and this severe drug-induced presentation, and emphasizes the critical implications for patient management, particularly concerning the acute manifestations of DKA. We also discuss its unique position within the broader classification of other types of diabetes and drug-induced etiologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.